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Case report
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Perivascular epithelioid cell tumor (PEComa) of the 
ascending colon: the implication of IFN-α 2b treatment
A 7-year-old boy presented with hematochezia and abdominal 
pain. A 3.7-cm-sized mass was identified in the ascending colon by 
abdominal computed tomography and colonoscopy. The patient 
underwent surgical resection. Pathological examination revealed a 
low-grade perivascular epithelioid cell tumor (PEComa). PEComa in 
the colon is very rare. Only a few cases have been reported so far. An 
effective treatment method for this rare tumor has not been established 
yet. The patient received adjuvant interferon-α immunotherapy for 1 
year. He has been tumor-free for 26 months since the initial diagnosis. 
This report is the first documented case of the use of interferon-α for 
pediatric PEComa of the colon.
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Introduction
Perivascular epithelioid cell tumor (PEComa) is a family of 
related mesenchymal neoplasms that include angiomyolipoma, 
lymphangiomyomatosis and clear cell ‘sugar’ tumor of the lung, 
and a group of rare, morphologically and immunophenotypically 
similar lesions arising at a variety of visceral and soft tissue sites
1).  It 
has distinct histological and immunohistochemical features defined 
by coexpression of melanocytic (HMB-45) and smooth muscle 
markers (smooth muscle actin and desmin), but negativity to S-100 
protein
2). Data on gastrointestinal (GI) PEComa remain limited to 
isolated case reports. To our knowledge, 17 cases have been reported 
in the literature, among which 10 occurred in adults
3). Because 
of the rarity of PEComa, its clinical, phenotypic and biological 
characteristics are not fully understood, and little is known about 
prognosis and treatment modalities for PEComa. The mainstream 
treatment is surgical excision. However, chemotherapy and 
radiotherapy have been used in locally advanced, metastatic and 
histologically malignant cases. We report a child with PEComa in 
the ascending colon, treated by surgical excision and interferon-α 2b 
(IFN-α 2b) immunotherapy. 
Case report
A previously healthy 7-year-old boy was admitted to our hospital 
because of hematochezia and abdominal pain. There was no history 
of bleeding disorders, recent infection, change in bowel habits, or 
significant weight loss. Family history was not specific. Physical 
examination revealed tenderness in the periumbilical area. On 
digital rectal exam, there was some gross blood mixed with soft 976      SI Park, et al. • Clinical characteristics of children with 2009 influenza A (H1N1)
stool. A complete blood count showed white blood cell 11,500/
mm3, hemoglobin 8.2 g/dL, hematocrit 26.0%, mean corpuscular 
volume 72.4 fL, platelet 401,000/mm
3 and other biochemical 
tests were normal. A Meckel scan was negative. Abdominal 
computed tomography (CT) (Fig. 1A) and colonoscopy displayed 
a 3.9 cm-sized pedunculated mass at the hepatic flexure of the 
ascending colon. Surgical resection and right hemicolectomy was 
performed. Examination of the resected colon revealed a 4×3 cm 
in size, polypoid, yellow and partially brown mass (Fig. 1B). The 
tumor cells were predominantly epithelioid cells having prominent 
nuclei and abundant cytoplasm (Fig. 2A), and they were positive 
for HMB-45 (Fig. 2B), but negative for S-100 protein, actin, and 
desmin. The diagnosis of intestinal PEComa was established. The 
tumor was low-grade malignancy as evidenced by infiltrative growth 
but mild cellular atypia, low mitotic and proliferation index without 
necrosis and no vascular invasion. All of the surgical margins were 
free of tumor. A metastatic workup including a bone scan, positron 
emission tomography, brain and chest CT was negative. He had no 
history of primary melanoma, and no stigmata of tuberous sclerosis. 
He was treated with adjuvant IFN-α 2b therapy (Intron-A
®, 
Schering-Plough, Kenilworth, New Jersey, New Jersey, USA): 3 
million IU/m
2, 3 times/week, subcutaneous injection, for 1 year. 
Short term side effects, such as fever, neutropenia and skin necrosis, 
were not seen in the present case. He has been free of disease under 
regular surveillance 26 months after initial diagnosis. 
Discussion  
A recently defined PEComa is a rare mesenchymal neoplasm of 
uncertain malignant potential affecting various organs. At first, 
Fig. 1. (A) Computed tomography of the abdomen showing a 3.9-cm pedunculated polyp in the right ascending 
colon. (B) Gross finding showing a 4×3 cm, yellow and brown, pedunculated mass at the hepatic flexure of the 
ascending colon. Multiple polyps in the small bowel were also visible.
Fig. 2. (A) Histopathological appearance of the tumor consisting of nests of epithelioid cells with eosinophilic 
granular cytoplasm. The nuclei of tumor cells were small and round to oval in shape (Hematoxylin & Eosin staining; 
×200). (B) Immunohistochemical features of the tumor showing expression of HMB-45 antigen (HMB-45; ×200). Korean J Pediatr 2010;53(11):975-978 • DOI: 10.3345/kjp.2010.53.11.975    977
Bonetti et al
4) proposed the concept of perivascular epithelioid cell 
(PEC) in 1992 and the terminology ‘PEComa’ was suggested by 
Zamboni et al
5) in 1996. The World Health Organization accepted 
the designation ‘PEComas,’ defining them as mesenchymal 
neoplasms that share the same distinctive cell type, the PEC in 
2002.
PEComas have been reported in several organs including the 
uterus, falciform ligament, prostate, small and large bowel, rectum, 
lung, breast, cardiac septum, liver, kidney, pancreas and soft tissue 
of the thigh. A review of 51 cases of PEComa documented in the 
literature revealed that 90% of cases affected females and 41% 
involved the uterus
6). In the pediatric population, there have been 
only a few documented PEComas in several organs including the 
duodenum, appendix, transverse colon, sigmoid colon, rectum, 
kidney, broad ligament, vagina and orbit. To our knowledge, 
17 cases of GI PEComas have been reported in the literature, 
among which 10 occurred in adults
3). Pediatric GI PEComas 
were documented in rectum
3, 7, 8), appendix
9), duodenum
10), 
sigmoid colon
11) and transverse colon
12). This report is the eighth 
documented case of the pediatric GI PEComa, and the third 
documented case of the pediatric colon PEComa. 
PEComa has distinctive morphologic, immunohistochemical, 
ultrastructural and genetic features. The tumor cells have 
large epithelioid appearance with abundant clear to granular 
eosinophilic cytoplasm and a large vesicular nucleus. No nor-
mal cellular counterpart has been recognized for these cells. 
Immunohistochemically, PEComa expresses myogenic and 
melanocytic markers, such as HMB45, HMSA-1, MelanA/
Mart1, microophthalmia transcription factor (Mitf), actin and, 
less commonly, desmin
13). On ultrastructural analysis, PEComa 
contains microfilament bundles with electron-dense condensation, 
numerous mitochondria and membrane-bound dense granules.
Little information is available on the possible molecular altera-
tions occurring in PEComas. In one report, the loss of chromosome 
X and a t(3;10) translocation were identified by conventional 
cytogenetic techniques
14). In another report, no gain or loss of 
chromosomal material was shown by comparative genomic 
hybridization
6). Chromosomal study was not granted for this case.
Histologic criteria indicative of malignant potential in PEComas 
have not been established, especially in the pediatric age group. 
However, in a recent study of PEComa of soft tissue and gynecologic 
origin, Folpe et al
15) suggested criteria to separate PEComas into 
benign, uncertain malignant potential, and malignant categories. 
They proposed that malignancy was predicted by the presence 
of 2 or more of the followings: tumor size greater than 5 cm, 
infiltrative tumor border, high nuclear grade and cellularity; more 
than 1 mitosis/50 high-power fields, tumor necrosis, and vascular 
invasion. In the present case his tumor was regarded as low grade, as 
evidenced by infiltrative tumor border but lacking of other findings 
listed above. 
Optimal treatment for PEComas needs to be established. 
Primary excision is usually curative, as most tumors are benign. 
However, locally advanced or metastatic disease portends a poor 
prognosis and strategies incorporating chemotherapy, radiation 
and immunotherapy have been reported. Various responses, 
including complete, partial or absent responses, have been noted 
for dacarbazine, vincristine and imatinib mesylate. Rigby et al
16) 
reported an 11-year-old girl with metastatic renal PEComa treated 
with dacarbazine based chemotherapy and imatinib mesylate. She 
presented with two large abdominal masses in the left flank and 
epigastrium and left supraclavicular lymphadenopathy. The tumor 
did not respond to an initial treatment of chemotherapy, including 
dacarbazine, BiCNU and vincristine. A trial of imatinib mesylate 
based on the expression of c-KIT was unsuccessful because of the 
lack of response and adverse effects of the drug. 
Among 7 pediatric GI PEComa cases reported so far, six were 
treated with surgery alone
7-12), and the last was treated with surgery 
and adjuvant chemotherapy consisting of doxorubicin, ifosfamide, 
and mesna on the basis of non-rhabdomyosarcoma soft tissue 
sarcoma protocol ARST0332 by Children’s Oncology Group
3).    
Adjuvant IFN-α 2b was used in patients with melanoma
17), and 
for immunotherapy in a patient with PEComa of the bladder
18). 
IFN-α 2b was also used for other solid tumors. It reduced neo-
microvascular density in the normal urothelium adjacent to the 
tumor after transurethral resection of superficial bladder car-
cinoma
19). Outpatient treatment with subcutaneous IFN-α 2b plus 
interleukin-2 treatment for metastatic renal cell cancer was also 
reported. Eight of 47 patients (17%) responded to this regimen 
and overall response rate was similar to that seen with high-dose 
interleukin-2 alone, however, the response duration appeared to 
be shorter
20). While IFN-α 2b therapy for the management of 
PEComa remains experimental, we decide to use IFN-α 2b based 
on the vascular nature of this tumor and its anti-angiogenic effect. 
The present case represents the first documented pediatric GI 
PEComa treated with surgical resection and adjuvant IFN-α 2b 
immunotherapy. Further studies involving larger number of cases 
and close monitoring by long-term follow-up are required in the 
light of its potential for local recurrence and distant metastasis. 
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